Regular articleAltered arginine metabolism in Alzheimer's disease brains
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative condition with memory loss as an early prognostic sign and aging as a major risk factor. Its cardinal histopathological features consist of aggregates of hyperphosphorylated tau and amyloid beta (Aβ), which form intracellular neurofibrillary tangles (NFTs) and extracellular senile plaques (SPs), respectively, in the affected brain regions. Although Aβ plays a central and causative role in the disease development (Hardy and Higgins, 1992, Selkoe, 2011), a growing body of evidence suggests the involvement of arginine metabolism in AD pathogenesis (Law et al., 2001, Malinski, 2007, Yi et al., 2009).
L-arginine is a semi-essential amino acid that can be metabolized to form a number of bioactive molecules (Fig. 1; Wu and Morris, 1998). Nitric oxide (NO) is a gaseous signaling molecule produced by NO synthase (NOS). NO derived from neuronal NOS (nNOS) plays an important role in synaptic plasticity and learning and memory (Feil and Kleppisch, 2008, Susswein et al., 2004, Zhou and Zhu, 2009), whereas endothelial NOS (eNOS)-derived NO is a key factor for the stabilization and regulation of the vascular microenvironment (de la Torre, 2012, Forstermann and Sessa, 2012). In AD brains, NFTs and SPs are associated with reduced capillary expression of eNOS (Jeynes and Provias, 2009, Provias and Jeynes, 2008). There is evidence suggesting that eNOS-derived NO can directly modulate the production of Aβ and protect against increases in Aβ (Austin et al., 2010). Because of its nature as a free radical, however, an excessive amount of NO, particularly that derived from inducible NOS (iNOS), leads to neurotoxicity and neurodegeneration (Law et al., 2001, Malinski, 2007). It has been reported that NO produced in response to Aβ triggers mitochondrial fission, synaptic loss, and neuronal damage (Cho et al., 2009).
L-ornithine is the arginase-mediated metabolite of L-arginine, with urea as the by-product (Fig. 1). It can be metabolized by ornithine decarboxylase (ODC) to produce the polyamines putrescine, spermidine, and spermine (Fig. 1), which are essential for cells to grow and to function in an optimal manner (Alm and Oredsson, 2009, Igarashi and Kashiwagi, 2010, Wallace, 2009, Wallace et al., 2003). In AD brains, there is altered arginase I and arginase II messenger RNA (mRNA) expression, ODC protein expression, and polyamine tissue concentrations (Colton et al., 2006, Hansmannel et al., 2010, Morrison and Kish, 1995, Morrison et al., 1998). Moreover, the arginase II allele rs742869 is associated with an increased risk of earlier onset AD (Hansmannel et al., 2010). L-ornithine can also be channeled to produce glutamate that can be further metabolized to generate γ-aminobutyric acid (GABA) and glutamine by glutamic acid decarboxylase and glutamine synthase (GS), respectively (Fig. 1; Tapiero et al., 2002, Wiesinger, 2001, Wu and Morris, 1998). Previous research has reported decreased glutamate and GABA levels in AD brains and increased GS level in lumbar cerebrospinal fluid of AD patients (Ellison et al., 1986, Tumani et al., 1999).
Agmatine is the product of arginine decarboxylase (ADC) (Wu and Morris, 1998), and is present in mammalian brain (Li et al., 1994). Agmatine inhibits nNOS and iNOS, but stimulates eNOS, hence it has an important role in regulating NO production (Halaris and Plietz, 2007, Joshi et al., 2007, Santhanam et al., 2007, Satriano, 2003). As agmatine can itself be metabolized by agmatinase to form putrescine (Fig. 1) and induce antizyme, a small regulatory protein that inhibits ODC and down-regulates polyamine uptake (Satriano, 2003), it has an important role in controlling cellular polyamine content. Moreover, agmatine is considered a novel putative neurotransmitter (Reis and Regunathan, 2000), and recent evidence suggests its involvement in learning and memory processes (Leitch et al., 2011, Liu et al., 2008b, Liu et al., 2009a, Rushaidhi et al., 2013, Seo et al., 2011). To the best of our knowledge, there is no previous research on how agmatine changes in AD brains.
Metabolomics refers to the analysis of the component small molecules produced by a biological system and is playing an increasingly prominent role in efforts at biomarker identification for AD (Trushina and Mielke, 2013, Trushina et al., 2013). As described previously, L-arginine is versatile metabolically but its involvement in AD is largely based on scattered information from a single pathway. Hence, it is essential to understand how the arginine metabolic profile changes in AD brains. In the present study, we systematically compared NOS and arginase activity and protein expression, as well as the tissue concentrations of L-arginine and its 9 downstream metabolites in postmortem superior frontal gyrus, hippocampus, and cerebellum from AD cases (mean age 80 years) and normal control cases (mean age 60 or 80 years). This experimental design allowed us to assess the effects of AD, as well as advanced aging, on arginine metabolism in the brain. Since the hippocampus and superior frontal gyrus are more vulnerable in AD, whereas the cerebellum is less affected (Braak and Braak, 1991, Serrano-Pozo et al., 2011), we investigated whether the L-arginine metabolic profile changes are region-specific.
Section snippets
Human samples
Human brain tissue was obtained from the Neurological Foundation of New Zealand Human Brain Bank. All tissue collection protocols were approved by the University of Auckland Human Participants Ethics Committee, and informed consent was obtained from all families. The unfixed snap-frozen superior frontal gyrus (SFG; central portion), hippocampus (HPC; anterior portion), and cerebellum (CE; anterior lobe) were obtained from 11 neurologically normal cases with an average age of 60 years (NC-60;
AD- and age-related changes in NOS activity and protein expression
The present study used the radioenzymatic assay to determine the total NOS (in the presence of co-factors) and iNOS (in the absence of calcium) activities in the superior frontal gyrus, hippocampus, and cerebellum across the 3 groups. The total NOS activity was significantly different between groups in SFG (F = 15.97, p < 0.0001), HPC (F = 22.79, p < 0.0001), and CE (F = 6.04, p < 0.001), with markedly reduced levels in the AD-80 group relative to the NC-60 (all 3 regions, 60%–94% decrease) and
Discussion
L-arginine is a versatile amino acid that can be metabolized by NOS, arginase, and ADC to form a number of bioactive molecules (Wiesinger, 2001, Wu and Morris, 1998). The present study, for the first time, systematically compared its metabolic profile in the superior frontal gyrus, hippocampus, and cerebellum in the neurologically normal cases with an average age of 60 (NC-60) or 80 (NC-80) years and AD cases with an average age of 80 years (AD-80). Because there were no significant differences
Conclusions
The present study, for the first time, demonstrates the effects of AD, as well as advanced aging, on the brain metabolic profile of L-arginine. There appear to be down-regulated NOS pathway (mainly nNOS and eNOS), with the superior frontal gyrus and hippocampus exhibiting AD- and age-related changes and the cerebellum only showing age-related alterations, and up-regulated arginase pathway (especially arginase II) specifically in AD brains. Immunohistochemistry confirmed the presence of iNOS in
Disclosure statement
The authors declare no conflicts of interest.
Acknowledgements
This work was supported by the Health Research Council of New Zealand (10/170) and the Neurological Foundation of New Zealand. The authors express their appreciation to the Alzheimer's families in New Zealand for their invaluable assistance, and to the Neurological Foundation of New Zealand Human Brain Bank. They also thank Jocelyn Bullock and Marika Eszes in the Department of Anatomy with Radiology, University of Auckland, and the technical staff in the Department of Anatomy and School of
References (89)
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
Anal. Biochem.
(1976)- et al.
Evidence that Alzheimer's disease is a microvascular disorder: the role of constitutive nitric oxide
Brain Res. Rev.
(2000) - et al.
Neurobiology of ammonia
Prog. Neurobiol.
(2002) - et al.
Ageing alters behavioural function and brain arginine metabolism in male Sprague-Dawley rats
Neuroscience
(2012) - et al.
Modulation of cellular function by polyamines
Int. J. Biochem. Cell Biol.
(2010) - et al.
Significant negative correlations between capillary expressed eNOS and Alzheimer lesion burden
Neurosci. Lett.
(2009) - et al.
Does vascular pathology contribute to Alzheimer changes?
J. Neurol. Sci.
(2012) - et al.
Scopolamine impairs behavioural function and arginine metabolism in the rat dentate gyrus
Neuropharmacology
(2011) - et al.
Say NO to Alzheimer's disease: the putative links between nitric oxide and dementia of the Alzheimer's type
Brain Res. Brain Res. Rev.
(2001) - et al.
Age-related changes in polyamines in memory-associated brain structures in rats
Neuroscience
(2008)
Pre-aggregated Abeta(25-35) alters arginine metabolism in the rat hippocampus and prefrontal cortex
Neuroscience
Age-related changes in arginine and its metabolites in memory-associated brain structures
Neuroscience
Regional variations and age-related changes in nitric oxide synthase and arginase in the sub-regions of the hippocampus
Neuroscience
A multivariate analysis of the effects of aging on glutamate, GABA and arginine metabolites in the rat vestibular nucleus
Hear. Res.
Expression of endothelial and inducible NOS-isoforms is increased in Alzheimer's disease, in APP23 transgenic mice and after experimental brain lesion in rat: evidence for an induction by amyloid pathology
Brain Res.
Brain polyamine levels are altered in Alzheimer's disease
Neurosci. Lett.
Neuronal nitric oxide synthase (nNOS) mRNA expression and NADPH-diaphorase staining in the frontal cortex, visual cortex and hippocampus of control and Alzheimer's disease brains
Brain Res. Mol. Brain Res.
Agmatine: clinical applications after 100 years in translation
Drug Discov Today
Is agmatine a novel neurotransmitter in brain?
Trends Pharmacol. Sci.
Participation of hippocampal agmatine in spatial learning: an in vivo microdialysis study
Neuropharmacology
Activation of protein kinase B/Akt and endothelial nitric oxide synthase mediates agmatine-induced endothelium-dependent relaxation
Eur. J. Pharmacol.
Ammonia and Alzheimer's disease
Neurochem. Int.
Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease
Neurobiol. Aging
Spatial learning-induced accumulation of agmatine and glutamate at hippocampal CA1 synaptic terminals
Neuroscience
II. Glutamine and glutamate
Biomed. Pharmacother.
nNOS expressing neurons in the entorhinal cortex and hippocampus are affected in patients with Alzheimer's disease
Exp. Neurol.
Cerebellar atrophy in Alzheimer's disease-clinicopathological correlations
Brain Res.
Arginine metabolism and the synthesis of nitric oxide in the nervous system
Prog. Neurobiol.
Advanced glycation endproducts co-localize with inducible nitric oxide synthase in Alzheimer's disease
Brain Res.
Nitric oxide synthase neurons in different areas of normal aged and Alzheimer's brains
Neuroscience
Neuronal nitric oxide synthase: structure, subcellular localization, regulation, and clinical implications
Nitric Oxide
Nitric oxide as an initiator of brain lesions during the development of Alzheimer disease
Neurotox. Res.
Cells and polyamines do it cyclically
Essays Biochem.
Asymmetrical dimethylarginine is increased in plasma and decreased in cerebrospinal fluid of patients with Alzheimer's disease
Dement. Geriatr. Cogn. Disord.
Endothelial nitric oxide modulates expression and processing of amyloid precursor protein
Circ. Res.
Evidence for induction of the ornithine transcarbamylase expression in Alzheimer's disease
Mol. Psychiatry
Neuropathological stageing of Alzheimer-related changes
Acta Neuropathol.
Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme
Proc. Natl. Acad. Sci. U.S.A
S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury
Science
Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD
J. Neuroinflammation
Cerebral hemodynamics and vascular risk factors: setting the stage for Alzheimer's disease
J. Alzheimers Dis.
A postmortem study of amino acid neurotransmitters in Alzheimer's disease
Ann. Neurol.
NO/cGMP-dependent modulation of synaptic transmission
Handb. Exp. Pharmacol.
Hyperammonemia in Alzheimer's disease
Am. J. Psychiatry
Cited by (132)
Metabolomic of neurodegenerative disorder: Alzheimer's disease
2024, Comprehensive Analytical ChemistryRegional investigation of UT-B urea transporters in the rat brain
2023, Biochemistry and Biophysics ReportsNeuroprotection by agmatine: Possible involvement of the gut microbiome?
2023, Ageing Research ReviewsChanges in arginine metabolism in advanced Alzheimer's patients: Experimental and theoretical analyses
2023, Journal of Molecular Structure